Table 3 Median overall survival durations in subgroups based on combined hENT1 and DPD tumour expression status

From: Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

Treatment arm

Subgroup

Number of patients

Median overall survival (95% CI) months

P value (raw)

P value post Bonferroni correction

5-fluorouracil with folinic acid

hENT1-high DPD-high

9

17.3 (0.6–38.0)

0.81

1.000

hENT1-high DPD-low

39

26.0 (19.8–30.1)

  

hENT1-low DPD-high

17

9.7 (5.3–30.4)

0.002

0.014

hENT1-low DPD-low

47

29.2 (19.5–41.9)

  

Gemcitabine

hENT1-high DPD-high

12

22.3 (9.6–39.5)

0.060

0.360

hENT1-high DPD-low

57

26.3 (17.2–33.0)

  

hENT1-low DPD-high

11

14.0 (9.1–15.7)

0.730

1.000

hENT1-low DPD-low

38

18.0 (7.6–15.3)

  
  1. Data in bold indicate significant relationships.